Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q73355996)
Watch
English
Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomised trials among 3948 patients
scientific article published on 01 November 2000
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PubMed ID
11142483
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11142483%20AND%20SRC:MED&resulttype=core&format=json
retrieved
3 November 2019
meta-analysis
0 references
title
Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomised trials among 3948 patients
(English)
1 reference
stated in
Europe PubMed Central
PubMed ID
11142483
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11142483%20AND%20SRC:MED&resulttype=core&format=json
retrieved
3 November 2019
main subject
meta-analysis
1 reference
based on heuristic
inferred from title
multiple myeloma
1 reference
based on heuristic
inferred from title
author name string
E Fritz
series ordinal
1
1 reference
stated in
Europe PubMed Central
PubMed ID
11142483
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11142483%20AND%20SRC:MED&resulttype=core&format=json
retrieved
3 November 2019
H Ludwig
series ordinal
2
1 reference
stated in
Europe PubMed Central
PubMed ID
11142483
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11142483%20AND%20SRC:MED&resulttype=core&format=json
retrieved
3 November 2019
publication date
1 November 2000
1 reference
stated in
Europe PubMed Central
PubMed ID
11142483
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11142483%20AND%20SRC:MED&resulttype=core&format=json
retrieved
3 November 2019
published in
Annals of Oncology
1 reference
stated in
Europe PubMed Central
PubMed ID
11142483
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11142483%20AND%20SRC:MED&resulttype=core&format=json
retrieved
3 November 2019
volume
11
1 reference
stated in
Europe PubMed Central
PubMed ID
11142483
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11142483%20AND%20SRC:MED&resulttype=core&format=json
retrieved
3 November 2019
page(s)
1427-1436
1 reference
stated in
Europe PubMed Central
PubMed ID
11142483
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11142483%20AND%20SRC:MED&resulttype=core&format=json
retrieved
3 November 2019
issue
11
1 reference
stated in
Europe PubMed Central
PubMed ID
11142483
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11142483%20AND%20SRC:MED&resulttype=core&format=json
retrieved
3 November 2019
cites work
Interferon therapy in myelomatosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1023%2FA%3A1026548226770
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Treatment of multiple myeloma with recombinant interferon alfa-2a
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1023%2FA%3A1026548226770
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Alpha-2a-interferon/melphalan/prednisone versus melphalan/prednisone in previously untreated patients with multiple myeloma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1023%2FA%3A1026548226770
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A randomised trial of cyclophosphamide with and without low dose alpha-interferon in the treatment of newly diagnosed myeloma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1023%2FA%3A1026548226770
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1023%2FA%3A1026548226770
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Interferon alfa-2b versus no maintenance therapy during the plateau phase in multiple myeloma: a randomized study. Cooperative Study Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1023%2FA%3A1026548226770
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Double hemibody irradiation (DHBI) in the management of relapsed and primary chemoresistant multiple myeloma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1023%2FA%3A1026548226770
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A randomized clinical trial comparing melphalan/prednisone with or without interferon alfa-2b in newly diagnosed patients with multiple myeloma: a Cancer and Leukemia Group B study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1023%2FA%3A1026548226770
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A comparison of polychemotherapy and melphalan/prednisone for primary remission induction, and interferon-alpha for maintenance treatment, in multiple myeloma. A prospective trial of the German Myeloma Treatment Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1023%2FA%3A1026548226770
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1023%2FA%3A1026548226770
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1023%2FA%3A1026548226770
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Obtaining data from randomised controlled trials: how much do we need for reliable and informative meta-analyses?
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1023%2FA%3A1026548226770
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Interferon-alpha for induction and maintenance in multiple myeloma: results of two multicenter randomized trials and summary of other studies
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1023%2FA%3A1026548226770
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Interferon-alpha 2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma. A randomized, controlled trial. The Nordic Myeloma Study Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1023%2FA%3A1026548226770
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Australian Leukaemia Study Group myeloma II: a randomized trial of intensive combination chemotherapy with or without interferon in patients with myeloma.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1023%2FA%3A1026548226770
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Alternating combination chemotherapy and interferon improves survival in poor prognosis multiple myeloma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1023%2FA%3A1026548226770
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase III study comparing vincristine, doxorubicin (Adriamycin), and dexamethasone (VAD) chemotherapy with VAD plus recombinant interferon alfa-2 in refractory or relapsed multiple myeloma. An Eastern Cooperative Oncology Group study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1023%2FA%3A1026548226770
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Impact of interferon at induction chemotherapy and maintenance treatment for multiple myeloma. Preliminary results of a multicenter study by the Italian non-Hodgkin's Lymphoma Cooperative Study Group (NHLCSG)
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1023%2FA%3A1026548226770
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
MRC trial of alpha2b-interferon maintenance therapy in first plateau phase of multiple myeloma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1023%2FA%3A1026548226770
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1023%2FA%3A1026548226770
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Maintenance treatment with interferon alpha-2b in multiple myeloma: a prospective randomized study from PETHEMA (Program for the Study and Treatment of Hematological Malignancies, Spanish Society of Hematology).
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1023%2FA%3A1026548226770
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Single agent versus combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: a meta-analysis of response, toxicity, and survival
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1023%2FA%3A1026548226770
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cost-effectiveness of interferon in chronic myeloid leukaemia: analysis of four clinical studies.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1023%2FA%3A1026548226770
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Meta-analysis in clinical trials
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1023%2FA%3A1026548226770
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Summing up evidence: one answer is not always enough.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1023%2FA%3A1026548226770
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Gains in life expectancy from medical interventions--standardizing data on outcomes
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1023%2FA%3A1026548226770
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Quality-adjusted time without symptoms or toxicity analysis of interferon maintenance in multiple myeloma.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1023%2FA%3A1026548226770
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Patient preferences for interferon alfa in multiple myeloma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1023%2FA%3A1026548226770
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Effect of interferon on the health-related quality of life of multiple myeloma patients: results of a Nordic randomized trial comparing melphalan-prednisone to melphalan-prednisone + alpha-interferon. The Nordic Myeloma Study Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1023%2FA%3A1026548226770
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cost-utility analysis of melphalan plus prednisone with or without interferon-alpha 2b in newly diagnosed multiple myeloma. Results from a randomised controlled trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1023%2FA%3A1026548226770
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Identifiers
DOI
10.1023/A:1026548226770
1 reference
stated in
Europe PubMed Central
PubMed ID
11142483
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11142483%20AND%20SRC:MED&resulttype=core&format=json
retrieved
3 November 2019
PubMed ID
11142483
1 reference
stated in
Europe PubMed Central
PubMed ID
11142483
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11142483%20AND%20SRC:MED&resulttype=core&format=json
retrieved
3 November 2019
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
